Literature DB >> 32864893

Enhanced In Vivo Vascularization of 3D-Printed Cell Encapsulation Device Using Platelet-Rich Plasma and Mesenchymal Stem Cells.

Jesus Paez-Mayorga1,2, Simone Capuani1, Marco Farina1,3, Maria Luisa Lotito1,4, Jean A Niles5, Hector F Salazar1, Jessica Rhudy1, Lucas Esnaola1, Corrine Ying Xuan Chua1, Francesca Taraballi6,7, Bruna Corradetti1,8, Kathryn A Shelton9, Pramod N Nehete9,10, Joan E Nichols5, Alessandro Grattoni1,11,12.   

Abstract

The current standard for cell encapsulation platforms is enveloping cells in semipermeable membranes that physically isolate transplanted cells from the host while allowing for oxygen and nutrient diffusion. However, long-term viability and function of encapsulated cells are compromised by insufficient oxygen and nutrient supply to the graft. To address this need, a strategy to achieve enhanced vascularization of a 3D-printed, polymeric cell encapsulation platform using platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) is investigated. The study is conducted in rats and, for clinical translation relevance, in nonhuman primates (NHP). Devices filled with PRP, MSCs, or vehicle hydrogel are subcutaneously implanted in rats and NHP and the amount and maturity of penetrating blood vessels assessed via histopathological analysis. In rats, MSCs drive the strongest angiogenic response at early time points, with the highest vessel density and endothelial nitric oxide synthase (eNOS) expression. In NHP, PRP and MSCs result in similar vessel densities but incorporation of PRP ensues higher levels of eNOS expression. Overall, enrichment with PRP and MSCs yields extensive, mature vascularization of subcutaneous cell encapsulation devices. It is postulated that the individual properties of PRP and MSCs can be leveraged in a synergistic approach for maximal vascularization of cell encapsulation platforms.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  cell encapsulation; cell transplantation; mesenchymal stem cells; subcutaneous implants; vascularization

Mesh:

Substances:

Year:  2020        PMID: 32864893     DOI: 10.1002/adhm.202000670

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  8 in total

Review 1.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

Review 2.  Integrating Additive Manufacturing Techniques to Improve Cell-Based Implants for the Treatment of Type 1 Diabetes.

Authors:  Robert P Accolla; Amberlyn M Simmons; Cherie L Stabler
Journal:  Adv Healthc Mater       Date:  2022-04-22       Impact factor: 11.092

3.  Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; Simone Capuani; Robin Shae Vander Pol; Shani Zakiya Saunders; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2022-01-18       Impact factor: 15.304

Review 4.  Tailoring bioinks of extrusion-based bioprinting for cutaneous wound healing.

Authors:  Yuzhen Wang; Xingyu Yuan; Bin Yao; Shuoji Zhu; Ping Zhu; Sha Huang
Journal:  Bioact Mater       Date:  2022-01-29

5.  Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment.

Authors:  Simone Capuani; Nathanael Hernandez; Jesus Paez-Mayorga; Prashant Dogra; Zhihui Wang; Vittorio Cristini; Corrine Ying Xuan Chua; Joan E Nichols; Alessandro Grattoni
Journal:  Mater Today Bio       Date:  2022-08-11

Review 6.  Advanced strategies to thwart foreign body response to implantable devices.

Authors:  Simone Capuani; Gulsah Malgir; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Bioeng Transl Med       Date:  2022-03-02

Review 7.  Smart Porous Multi-Stimulus Polysaccharide-Based Biomaterials for Tissue Engineering.

Authors:  Fernando Alvarado-Hidalgo; Karla Ramírez-Sánchez; Ricardo Starbird-Perez
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

8.  Commentary: Insulin-Producing Organoids Engineered From Islet and Amniotic Epithelial Cells to Treat Diabetes.

Authors:  Lorenzo Cobianchi; Beat Moeckli; Stefania Croce
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-06       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.